Molecular Map Provides Clues To Zinc-Related Diseases Wednesday, June 22, 2016 Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.ASMS 2016: Targeting Mass Spectrometry Tools for the Masses Friday, June 17, 2016 The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas. Nanoprobe Enables Measurement of Protein Dynamics in Living Cells Thursday, June 16, 2016 Mass. General and Harvard researchers use device to measure how anesthetic affects levels of Alzheimer's-associated proteins.Protagen Announces CE Mark for its Proprietary Multilisa® BICD2 Test Thursday, June 16, 2016 BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).Diagnosing Systemic Infections Quickly, Reliably Wednesday, June 15, 2016 Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.What Makes a Good Scientist? Wednesday, June 15, 2016 It’s the journey, not just the destination that counts as a scientist when conducting research.A New Tool Brings Personalized Medicine Closer Tuesday, June 14, 2016 Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.Biotage Achieves ISO 14001:2004 Certification Tuesday, June 14, 2016 This certificate is an international standard for an environmental management system (EMS) that helps businesses such as Biotage control and improve practices that are potentially harmful to the environment. Blood Test That Detects Early Alzheimer’s Disease Monday, June 13, 2016 A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.